Substantial developments have occurred in the past 5–10 years in clinical translational
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …

Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …

Background Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2,
and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor …

Background Patients with radioactive iodine (131 I)-refractory locally advanced or metastatic
differentiated thyroid cancer have a poor prognosis because of the absence of effective …

Background No effective standard treatment exists for patients with radioiodine-refractory,
advanced differentiated thyroid carcinoma. We aimed to assess efficacy and safety of …

Anaplastic thyroid cancer (ATC) is one of the deadliest human cancers and it is less than 2%
of thyroid carcinomas (TCs). The standard treatment of ATC includes surgical debulking …

Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until
recently, there were limited therapeutic options. However, over the last decade our …

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN
Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid …

Context Many differentiated thyroid cancers (DTC) dedifferentiate and become radioactive
iodine (RAI)–refractory (RAIR) with worse outcomes. Targeted therapy (TTx) may …

The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …